Clinical trials: Bullous Dermatoses
Bullous Pemphigoid
Genetic Susceptibility and Influence of the Microbiomae in Bullous Pemphigoid
Autoimmune bullous dermatoses include pemphigus, bullous pemphigoid, pemphigoid gestationis, linear IgA dermatosis, mucous membrane pemphigoid, lichen planus pemphigoid, anti-p200 pemphigoid, epidermolysis bullosa acquisita and…
- Trial name
- MICROPB (NCT02874079)
- Testing
- Blood sample and cotton skin swabs
- Where
- France
- Volunteers
- 100 people
- Sponsor
- CHU de Reims
Autoimmune Bullous Dermatoses
Register of Autoimmune Bullous Dermatoses
Autoimmune bullous dermatoses are a group of diseases with chronic course. They are provoked by the production of autoantibodies against the dermal-epidermal junction or against the inter-keratinocyte junctions, resulting in the…
- Trial name
- REGIBUL (NCT02899923)
- Testing
- Data collection
- Where
- France
- Volunteers
- 750 people
- Sponsor
- CHU de Reims
Bullous Pemphigoid, Pruritus
Explore the Mechanisms of Pruritus in Bullous Pemphigoid Patients During Remission
The following is the investigators hypothesis regarding the pruritus of BP patients during remission. Anti-BP 180 IgE binds to dermal mast cells, inducing their activation and secretion of mediators after being cross-linked by…
- Trial name
- NCT01265082
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Bullous Pemphigoid, Pemphigoid
Ixekizumab in the Treatment of Bullous Pemphigoid
Recently, Interleukin (IL)-17 has been identified as a key driver of chronic inflammation in Bullous Pemphigoid (BP). Ixekizumab is a recombinant high-affinity fully human monoclonal antibody that targets IL-17A Immunoglobulin…
- Trial name
- NCT03099538
- Testing
- Ixekizumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Mayo Clinic
Bullous Pemphigoid
Efficacy and Safety of Omalizumab in Bullous Pemphigoid
The primary objective is to test the safety and efficacy of Xolair in the treatment of the autoimmune blistering disease, bullous pemphigoid (BP). This is a pilot, open label case-control study.
- Trial name
- NCT00472030
- Testing
- Omalizumab, prednisone
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Iowa
Pemphigus
Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus
Pemphigus is a severe autoimmune blistering disease mediated by circulating antibodies against certain proteins important for maintaining skin integrity.
- Trial name
- NCT00656656
- Testing
- Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine
- Where
- Germany
- Volunteers
- 23 people
- Sponsor
- University of Luebeck
Bullous Pemphigoid
Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid
The objective of the program is to provide patients with Bullous Pemphigoid (BP), that participated in the R668-BP-1902 (NCT04206553) phase 2/3 study, dupilumab treatment and evaluate the long-term safety of dupilumab.
- Trial name
- NCT05906706
- Testing
- dupilumab
- Sponsor
- Regeneron Pharmaceuticals
Pemphigus Vulgaris, Bullous Dermatoses
Comparative Analysis of the Th17 Cellular Response in Active and Inactive Pemphigus Vulgaris Patients
This study will compare the pattern of Th17 immune response in active and inactive pemphigus subjects. Skin and serum samples will be taken at the moment of enrollment.
- Conditions
- Pemphigus Vulgaris, Bullous Dermatoses, Autoimmune Diseases
- Trial name
- NCT04096222
- Where
- 2 sites in Mexico
- Volunteers
- 42 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Bullous Pemphigoid
A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
ARGX-113-2009 is an operationally seamless 2-part, phase 2/3, prospective, global, multicenter, randomized, double-blinded, placebo-controlled study to investigate the efficacy, safety, tolerability, immunogenicity…
- Trial name
- BALLAD (NCT05267600)
- Testing
- efgartigimod PH20 SC, Prednisone
- Where
- 129 sites in United States, Australia and 19 more
- Volunteers
- 98 people
- Sponsor
- argenx
Pemphigoid
Study of the Periodontal Microbiota in Gingival Cicatricial Pemphigoid Patients. Bicentric Pilot Study.
In patients with gingival cicatricial pemphigoid (CP), clinical experience has shown that periodontal treatment is beneficial in addition to medical treatment, because the latter does not always allow optimal gingival healing.
- Trial name
- NCT04555681
- Testing
- Collection of subgingival dental plaque
- Where
- 2 sites in France
- Volunteers
- 24 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Autoimmune Bullous Dermatosis, Glucocorticoids Toxicity
Investigating the Morbidity of Glucocorticoid Use in Patients With Autoimmune Bullous Diseases (AIBDs)
This project utilised the validated glucocorticoid toxicity index (GTI) tool to assess the morbidity of glucocorticoid-use in patients with autoimmune bullous disease.
- Trial name
- NCT05525065
- Testing
- GlucoCorticoid
- Where
- Australia
- Volunteers
- 138 people
- Sponsor
- Premier Specialists, Australia
Bullous Pemphigoid (BP)
rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects
Bullous pemphigoid (BP) is the most common of the autoimmune blistering skin diseases in Western Europe. [Joly 2012]The study will recruit the new onset or relapsing mild to moderate BP patients.
- Trial name
- NCT04035733
- Testing
- rVA576
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 9 people
- Sponsor
- AKARI Therapeutics
Bullous Pemphigoid
Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment
To evaluate the safety and efficacy of QGE031 versus placebo in patients with bullous pemphigoid. Efficacy will be assessed as a reduction of disease activity.
- Trial name
- NCT01688882
- Testing
- QGE031
- Where
- 9 sites in United States, Austria and 4 more
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Bullous Pemphigoid
Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid
The aim of the study is to assess that it will be possible to control with a single cycle of rituximab patient with bullous pemphigoid.
- Trial name
- Rituximab2 (NCT00525616)
- Testing
- Mabthera
- Where
- France
- Volunteers
- 18 people
- Sponsor
- University Hospital, Rouen
Bullous Pemphigoid
Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids
Patients diagnosed with bullous pemphigoid were confirmed based on the investigators national diagnostic criteria. Patients who meet all inclusion criteria and do not conflict with the exclusion criteria will receive NPB-01…
- Trial name
- NCT01408550
- Testing
- NPB-01
- Where
- Japan
- Volunteers
- 56 people
- Sponsor
- Nihon Pharmaceutical Co., Ltd
Methemoglobinemia, Linear IgA Bullous Dermatosis
Pharmacokinetics and Distribution of Dapsone in Leucocytes After Single-dose and Multiple-dose Administration
The objectives of the study are to evaluate pharmacokinetics, distribution in blood leucocytes, metabolism and methemoglobinemia after single-dose and repeated-dose administration of 100 mg of dapsone in healthy subjects…
- Trial name
- NCT02493283
- Testing
- Dapsone single dose, Dapsone multiple dose, leucocytes
- Where
- Germany
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University Medicine Greifswald
Bullous Pemphigoid
Validation of a Simplified Severity Score (Investigator Global Assessment: IGA) in Bullous Pemphigoid
The aim of the study is to validate a global and simple score : IGA (Investigator Global Assessment) score for the evaluation of the extent and severity of the disease in patients with bullous pemphigoid
- Trial name
- IGA score (NCT05366127)
- Testing
- IGA score, BULLOUS PEMPHIGOID DISEASE AREA INDEX (BPDAI)
- Where
- 11 sites in France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Rouen
Bullous Pemphigoid
Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid
The study is an observational, multi-center, prospective, non-interventional and open-label data collection study assessing outcomes, treatment patterns, adverse events and costs in patients diagnosed with bullous pemphigoid.
- Trial name
- EDP-PB (NCT02837965)
- Testing
- treatment with topical superpotent corticosteroid therapy, treatment with systemic therapy (methotrexate), treatment systemic therapy (prednisone)
- Where
- France
- Volunteers
- 149 people
- Sponsor
- CHU de Reims
Bullous Pemphigoid
A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid
Bullous pemphigoid (BP) is a chronic, inflammatory, subepidermal, autoimmune blistering disease which mainly develops in the elderly, with onset usually in the late 70s and a substantial increase in incidence in people older than…
- Trial name
- NCT03286582
- Testing
- AC-203 1% Topical Ointment, Clobetasol 0.05% Topical Ointment
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- TWi Biotechnology, Inc.
Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP)
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
This is a long-term extension trial of RAY121 in patients with immunological diseases such as antiphospholipid syndrome (APS), bullous pemphigoid (BP), Behçet's Syndrome (BS), dermatomyositis (DM), immune-mediated necrotizing…
- Conditions
- Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
- Trial name
- NCT06723106
- Testing
- RAY121
- Where
- 62 sites in Australia, Austria and 17 more
- Volunteers
- 144 people
- Sponsor
- Chugai Pharmaceutical